Jiangsu Recbio Technology Co Ltd (HKSE:02179) Share Price

Company Profile

Business description
Jiangsu Recbio Technology Co Ltd is a vaccine company focused on the research, development, and commercialization of vaccines, with a high-value vaccine portfolio driven by in-house technologies. It has built three vaccine technology platforms: novel adjuvants, protein engineering, and immune evaluation. The company's portfolio currently consists of various vaccines, covering diseases such as cervical cancer, herpes zoster, and respiratory syncytial virus. It has two core strategic products, namely REC610, a novel adjuvanted recombinant shingles vaccine, which is currently in the stage of marketing application in China, and REC603, a recombinant HPV 9-valent vaccine under phase three clinical trial.
Contact
No. 888 Yaocheng Avenue
Medical High-tech District
Jiangsu Province
Taizhou
CHN
T: +86 52386818860
https://www.recbio.cn
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
466

Recommended

International expansion is a distraction from valuable local business.

Roy Van Keulen | 14 May 2026

The chipmaker’s IPO priced at $185, well above its initial range, and opened trading at an eye-popping $350.

Jacob Robbins | 14 May 2026

How the most traded shares in April stack up against our analysts views.

Tyger Fitzpatrick | 14 May 2026

Index	Last price	Change	% Change
All Ordinaries	8,870.60	46.70	-0.52%
CAC 40	7,952.55	129.72	-1.61%
DAX 40	23,950.57	505.69	-2.07%
Dow JONES (US)	49,526.17	537.29	-1.07%
FTSE 100	10,195.37	177.56	-1.71%
HKSE	25,962.73	426.31	-1.62%
NASDAQ	26,225.14	410.08	-1.54%
Nikkei 225	61,409.29	1,244.76	-1.99%
NZX 50 Index	12,965.01	60.06	-0.46%
S&P 500	7,408.50	92.74	-1.24%
S&P/ASX 200	8,630.80	42.70	-0.49%
SSE Composite Index	4,135.39	42.53	-1.02%